A Phase 3 interventional study of Golcadomide and Placebo in Large B-cell Lymphoma, sponsored by Celgene. Active, not recruiting at 325 sites in 38 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Lymphoma by Bristol-Myers Squibb — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Bristol-Myers Squibb.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one has the largest planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 40th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →2 of the 42 studies in Lymphoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, France, Germany
Ages 18+
Turning Point Therapeutics, Inc. · Sites in United States, Australia, Canada and 8 more countries
Ages up to 25
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 17 · Phase 3 5
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 850 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 74 across the 39 interventional studies, 151 across the 3 observational. Of the 36 that completed or were terminated, 17 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
1 of the studies in Lymphoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including:
i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified [including germinal center B-cell (GCB) and activated B-cell (ABC) types]
ii) High-grade B-cell lymphoma, with MYC and BCL2 rearrangements (HGBL-MYC/BCL2 double-hit lymphomas)
iii) High-grade B-cell lymphoma, not otherwise specified
iv) T-cell/histiocyte/rich large B-cell lymphoma (THRLBCL)
v) Epstein-Barr virus + DLBCL
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Golcadomide · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Drug: Placebo · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Specified dose on specified days
Also known as: BMS-986369, CC-99282
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Progression-free survival (PFS) assessed by the Investigator
Time frame: Approximately 24 months after the last participant's first treatment
PFS assessed by the Investigator
Time frame: Approximately 24 months after the last participant's first treatment
Overall survival (OS)
Time frame: Up to approximately 67 months
Event-free survival (EFS)
Time frame: Approximately 24 months after the last participant's first treatment
Complete Metabolic Response assessed by the Independent Response Adjudication Committee (IRAC)
Time frame: Up to approximately 18 weeks
Minimal residual disease (MRD) negativity rate
Time frame: Up to approximately 18 weeks
Progression-free survival (PFS) assessed by the IRAC
Time frame: Approximately 24 months after the last participant's first treatment
Objective response (OR) assessed by the Investigator
Time frame: Up to approximately 18 weeks
Complete metabolic response (CMR) assessed by the Investigator
Time frame: Up to approximately 18 weeks
PFS24 assessed by the Investigator 24 months after randomization
Time frame: Up to 24 months
Duration of response (DoR)
Time frame: Up to approximately 67 months
Second progression-free survival (PFS2) assessed by the Investigator
Time frame: Up to approximately 67 months
Relative dose intensity (%)
Time frame: Up to 18 weeks
Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire
Time frame: Up to approximately 67 months
Time from randomization to meaningful improvement in primary domains of interest in the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) Questionnaire
Time frame: Up to approximately 67 months
Mean change from baseline in the EORTC QLQ-C30
Time frame: Up to approximately 67 months
Mean change from baseline in the FACT-LymS
Time frame: Up to approximately 67 months
Number of participants with Adverse Events (AEs)
Time frame: Up to approximately 22 weeks
Number of participants with treatment-emergent adverse events (TEAEs)
Time frame: Up to approximately 22 weeks
Number of participants with laboratory abnormalities
Time frame: Up to approximately 22 weeks
Number of participants with vital sign abnormalities
Time frame: Up to approximately 22 weeks
Showing the first 100 of 325 sites across 38 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 37 months after the start.
Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's planned 37 months is below that.
Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golcadomide